Hepato-Pancreatico-Biliary Cancers

Hepatocellular carcinoma starts in liver cells and has its own page because local treatments and the state of the liver dominate the plan. Pancreatic adenocarcinoma starts in the pancreas, often in the head, and is usually treated with chemotherapy when an operation is not possible. Bile-duct cancer, or cholangiocarcinoma, can start inside the liver, at the junction of the ducts, or outside the liver. Gallbladder cancer is less common and is sometimes found after the gallbladder has already been removed for stones. Each of these needs its own pathology line before a drug is chosen.

Neuroendocrine tumours of the pancreas are a separate family. They can grow more slowly and may be treated with different medicines or with hormone-related symptoms in mind. A cyst in the pancreas is often not cancer. Some cysts need surveillance and a few need surgery. The scan report’s exact wording matters more than the fear attached to the word pancreas.

Jaundice, dark urine, pale stools, itching, upper abdominal pain, and unexplained weight loss are the symptoms clinicians take seriously. Jaundice in a pancreatic or bile-duct cancer is often caused by a blocked duct. It can be relieved with a stent placed by a gastroenterologist, sometimes before any cancer treatment can safely start. Pain that goes through to the back, new diabetes, or greasy stools can occur with pancreatic disease. All of these symptoms have many causes that are not cancer, including stones and hepatitis.

Many of these cancers are found late because early disease is quiet. That fact is painful and it is not the patient’s fault. Once a scan suggests a mass, the useful next step is a timely specialist review, not a search for a single home explanation. Fever, worsening jaundice, or uncontrolled pain should not wait for a routine appointment.

A pancreatic-protocol CT, and sometimes MRI or endoscopic ultrasound, shows whether surgery might be possible. Tissue is obtained by endoscopic biopsy, by a needle, or at an operation. Chemotherapy should wait for a tissue diagnosis whenever that can be done safely. Blood tests look at bilirubin and liver function, because high bilirubin can delay some drugs until the blockage is drained. CA 19-9 is a blood marker that can be followed in some pancreatic and biliary cancers. It rises in blockage and inflammation as well, so it does not diagnose cancer by itself.

Stage is described in practical terms: whether a surgeon believes the tumour can be removed, whether it touches important vessels, and whether it has spread. Those categories can change after chemotherapy. A scan that says inoperable on the first day is not always the final word, and a scan that looks operable still needs a surgeon who operates on these cancers often. Medical oncology helps with the medicine around that decision. It does not declare an operation possible.

If surgeons consider a pancreatic or bile-duct tumour removable, chemotherapy may be discussed before or after the operation. The aim before surgery is to treat tiny spread early and sometimes to make the operation more likely to succeed. The aim after surgery is to lower the chance of return. If surgery is not possible, chemotherapy is often the main cancer treatment. Radiation is added in selected locally advanced cases by a radiation oncologist. Stents, drainage, and nerve blocks for pain are part of treatment even though they do not shrink the cancer.

The chemotherapy regimens used for pancreatic adenocarcinoma are different from those used for hepatocellular carcinoma. Bile-duct cancers overlap with pancreatic regimens in some settings and differ in others. Targeted therapy is relevant only for a minority, for example some tumours with a specific gene fusion, BRCA-related change, or other rare finding. Immunotherapy is not routine. A newer drug should be judged against the pathology, fitness, bilirubin, and what is actually appropriate. A web page cannot say that a new medicine fits one person.

Liver cancer within this group may still be treated with ablation, embolisation, or transplant pathways described on the liver cancer page. Gallbladder cancer found incidentally after a simple gallbladder operation may need a further operation and then a discussion about chemotherapy. That sequence is easy to miss if the first operation was done for stones and the cancer was a surprise. Bring that histology.

Pain, poor appetite, jaundice, itch, and difficulty digesting fat are common and treatable. Pancreatic enzyme capsules help some people whose pancreas no longer releases enough enzymes. They are taken with food and adjusted to symptoms. They are not cancer drugs. Blood sugar can rise and may need diabetes treatment. Clots in the veins are more common in pancreatic cancer and need medical advice if a leg swells or breathlessness starts suddenly.

Chemotherapy side effects include low blood counts, nausea, neuropathy, and fatigue, depending on the regimen. Fever during treatment is urgent. Nutrition support is considered when weight is falling quickly. Palliative care can begin at diagnosis, alongside chemotherapy, to handle pain and to help with decisions. Accepting that help does not mean chemotherapy has been stopped. It means symptoms are being taken as seriously as the tumour.

Scans during chemotherapy show whether the cancer is responding. A stent may need replacement if jaundice returns. After an operation, follow-up looks for recurrence and for late effects such as diabetes or digestive problems. If the cancer grows, a further line of chemotherapy or a targeted drug is discussed only when there is a reason to expect benefit and the person is well enough. Stopping active cancer treatment and focusing on comfort is also a legitimate plan. It should be an explicit choice, not a drift.

Family members often carry the appointments, the medicines, and the questions. They should be invited into the explanation of what treatment is trying to do. Goals change. A plan made at the first visit is reviewed when scans and strength change. Ask for that review rather than assuming the first prescription continues unchanged.

Bring the CT or MRI reports, any biopsy, bilirubin results, and the date a stent was placed if you have one. Note pain scores, weight change, itching, and whether stools have become pale. These details change whether chemotherapy can start or whether drainage must come first. If the gallbladder was removed and cancer was a surprise finding, bring that histology even if the operation felt routine.

Ask whether surgery is still being considered, what chemotherapy can and cannot do in that setting, and how pain, jaundice, and nutrition will be handled at the same time. Ask what should send you to hospital the same day. Families often hear different versions of inoperable. A single explanation, given while you are in the room, is kinder and more accurate than a corridor summary. This page is background for that conversation.

A visit about an HPB cancer is used to read the records you already have, explain them in plain language, and outline options that may apply. Bring the biopsy or pathology report, scan CDs or reports, blood tests, and a list of treatment already given, including dates and drug names if you have them. A family member can come with you. The visit is not an emergency assessment, and it does not confirm a plan until the records have been reviewed.

Dr. Nishith Vaddeboina is a medical oncologist. Appointments published on this website are at American Oncology Institute, Nallagandla, Hyderabad. The biography also lists consultant work at Renova Century Hospitals. Confirm the hospital when you book. Plans are discussed against recognised guidance, including NCCN, ESMO, and ASCO, and then adjusted to the person in the room. Nothing on this page replaces that conversation.

Jaundice, pale stools, persistent upper abdominal pain, or unexplained weight loss need assessment. Fever, vomiting, sudden breathlessness, or a swollen leg during treatment need urgent care. This page cannot tell a gallstone from a cancer.